PARK CITY, Utah — In this Healio Video Perspective from Clinical Trials at the Summit, Raj Agrawal, MD, discusses the initial results of a phase 2a study of a novel therapy for patients with diabetic macular edema.
Agrawal said RZ402 (Rezolute Bio), which is orally administered, demonstrated a significant change in central subfield thickness in the first-in-patient proof-of-concept study compared with placebo.
“I’m really excited about the fact that there is an oral medication that can potentially change the treatment paradigm for patients who currently have to keep coming